NEWS
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Repare Therapeutics presented new data at AACR's Ovarian Cancer Research Symposium, highlighting the impact of FBXW7, PPP2R1A, and CCNE1 alterations in metastatic ovarian and endometrial cancers. The analysis of approximately 2,000 patients revealed:
1. Ovarian cancer: Patients with these biomarkers (Lunre BM+) had a median overall survival (mOS) of 26 months compared to 36 months for those without (Lunre BM-), representing a 28% decrease in mOS.
2. Endometrial cancer: Lunre BM+ patients had an mOS of 30 months versus 41 months for Lunre BM- patients, a 27% decrease in mOS.
These findings underscore the need for innovative treatments for patients with these biomarkers. Repare's Phase 1 MYTHIC trial is studying the combination of lunresertib and camonsertib in patients with these biom
1. Ovarian cancer: Patients with these biomarkers (Lunre BM+) had a median overall survival (mOS) of 26 months compared to 36 months for those without (Lunre BM-), representing a 28% decrease in mOS.
2. Endometrial cancer: Lunre BM+ patients had an mOS of 30 months versus 41 months for Lunre BM- patients, a 27% decrease in mOS.
These findings underscore the need for innovative treatments for patients with these biomarkers. Repare's Phase 1 MYTHIC trial is studying the combination of lunresertib and camonsertib in patients with these biom
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2546Followers
107Following
28KVisitors
Follow